메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Duwa Ramesh (College of Pharmacy Keimyung University) 정지헌 (영남대학교) Yook Simmyung (계명대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제51권 제4호
발행연도
2021.1
수록면
465 - 481 (17page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background Parkinson’s disease (PD) is the most common progressive neurodegenerative disorder and is characterized by the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNC). To date, none of the strategies, such as pharmacological, non-pharmacological, and neurosurgical therapies, have been capable of fundamental treatment of PD. These types of treatments provide only symptomatic relief, and effective targeting for PD has lagged behind other disease areas, due to drug delivery challenges caused by the blood?brain barrier (BBB). Area covered This review focus on the immunologic and nanoformulation strategies used for the treatment of PD. In this review, we discuss the current strategies that offer the development of immunotherapies, antibody-based therapies, and nanoparticles (NPs)-based therapy to reduce the burden of degeneration of DA neurons due to synucleinopathies and elevation of proinflammatory cytokines in the central nervous system (CNS). Furthermore, this review presents current ongoing clinical trials. Expert opinion The accumulation and transmission of α-synuclein and activation of glial cells cause the death of dopaminergic neurons and lead to the progression of PD. Many studies have investigated the immunotherapies and NPs-based therapy that target α-synuclein, and microglia, which have been shown to effectively prevent the progression of α-synuclein deposition and microglia deactivation. Furthermore, at present, the formulations of different drugs, such as DA, levodopa (L-DOPA), monoamine oxidase inhibitors (MAO-I), and antioxidants, is administered with a multifunctional carrier that can penetrate the BBB. Therefore, rapid clinical progression on these strategies gives new hope in the therapy of PD.

목차

등록된 정보가 없습니다.

참고문헌 (119)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0